PROCEED: Treatment of Malignant Esophago-gastric Diseases - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn whether before surgery chemoradiotherapy with pembrolizumab followed by surgery improves how your cancer responds.

What is the Condition Being Studied?

Esophago-gastric cancer

Who Can Participate in the Study?

Adults with invasive esophageal, gastroesophageal or gastric adenocarcinoma that has not spread and who are planning to have chemoradiation before surgery.

Age Group

What is Involved?

If you join the study, you will have:
- a physical exam and other tests.
- Imaging scans (Computerized Tomography (CT) or Positron Emission Tomography (PET)),
- An endoscopic ultrasound
- 5 Blood samples
You will also:
- Receive Pembrolizumab combined with carboplatin, paclitaxel and radiation therapy before surgery
- Receive Pembrolizumab after surgery

Study Details

Full Title
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases. (PROCEED)
Principal Investigator
Radiation Oncologist
Protocol Number
IRB: PRO00081010
NCT: NCT03064490
Phase II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center